FDA Labeling Preemption Precludes Plaintiffs’ Failure-to-Warn Claims in MDL Targeting Vaccine
by Robert Johnston and Shannon Proctor
by Robert Johnston and Shannon Proctor
A recording of the 90-minute CLE is available.
A recognized authority on federal multi-district litigation (MDL), Gary writes and speaks frequently on issues related to MDL procedure and reform.
Hollingsworth LLP sponsored the webinar's CLE.
E.D.N.Y agreed with Northrop Grumman that it was entitled to summary judgment on all of plaintiff’s claims.
Firm attorney Varun Aery writes that defendants should highlight any misjoinder in removal papers.
Andrew Reissaus and Alexandra Stubblefield follow up on their previous article regarding the OTC decongestants MDL.
For over ten years, Eric Lasker has been a leading voice in the efforts to amend Rule 702 at both the federal and state levels.
Food industry businesses should be especially proactive in addressing potential liability before companies' mandatory reports on PFAS use become public.